H35.3212

🧬 ICD-10-CM H35.3212 — Exudative Age-Related Macular Degeneration, Right Eye, With Inactive Choroidal Neovascularization

Billable Code Confirmed

ICD-10-CM H35.3212 is a fully billable, 7-character ICD-10-CM code valid for FY2026, requiring no additional specificity. It classifies exudative (wet) age-related macular degeneration of the right eye specifically in the inactive choroidal neovascularization (CNV) stage, defined as involuted or regressed neovascularization. The 7-character structure encodes the condition type (H35.32), laterality via the 6th character (“1” = right eye), and disease activity stage via the 7th character (“2” = inactive CNV with involuted or regressed neovascularization). H35.3212 maps to CMS-HCC Category 300 under the V28 risk adjustment model, making it a high-priority risk adjustment capture code for Medicare Advantage populations.^1,2

Non-Billable Parent Codes

H35 (Other retinal disorders) is a 3-character non-billable category header — never submit on a claim. H35.32 (Exudative age-related macular degeneration) is a non-billable 5-character subcategory requiring both a laterality character (6th) and a stage character (7th) to reach billable specificity. H35.321 (Exudative AMD, right eye) is also non-billable at 6 characters — it still requires the 7th character stage digit; submitting H35.321 without the stage digit will result in a claim edit or denial. Per ICD-10-CM Official Guidelines, codes must be reported to their highest level of specificity, meaning H35.3210 through **H35.321**3 are the only billable options for right eye exudative AMD.^3,4

Clinical Context

ICD-10-CM H35.3212 is stage-specific, representing a patient whose wet AMD has been treated (typically with anti-VEGF intravitreal injections) and whose choroidal neovascularization has involuted or regressed — this is not a resolved condition, but rather a managed inactive phase that still requires ongoing surveillance and often continued treatment. The key clinical distinction driving code selection is CNV activity status: active CNV (H35.3211) signals ongoing leakage and typically active anti-VEGF treatment, while inactive CNV (H35.3212) reflects regression without complete scarring, and inactive scar (H35.3213) indicates fibrovascular scar formation with end-stage macular damage. Retinal imaging documentation — particularly OCT and OCT-A — is essential to support the stage specificity of H35.3212 in the medical record and withstand audit scrutiny.^4,5

Code Classification

ICD-10-CM H35.3212 is a diagnosis code (ICD-10-CM), not a procedure code — it describes the patient’s retinal condition and is used to support medical necessity for diagnostic and therapeutic procedures. It is a disease-of-the-eye code under Chapter 7 (H00-H59) and should not be confused with any CPT or HCPCS codes used to report the intravitreal injection or diagnostic imaging procedures performed to manage this condition.

---

🔍 Code Description

ICD-10-CM H35.3212 captures exudative (wet) age-related macular degeneration of the right eye in the inactive CNV phase — a clinical state in which pathological choroidal neovascularization has previously developed beneath the retinal pigment epithelium (RPE) and outer retina, causing subretinal or intraretinal fluid and macular damage, but in which that neovascular membrane has subsequently involuted or regressed, either spontaneously or in response to anti-VEGF pharmacotherapy. The “inactive” designation does not mean the patient is disease-free or no longer requires monitoring; rather, it reflects a treatment response phase characterized by absence of active leakage on OCT or fluorescein angiography, absence of new subretinal fluid, and stable or improving visual acuity. Patients in this phase are typically maintained on a treat-and-extend, pro re nata (PRN), or fixed-interval injection schedule, and reactivation of CNV is a constant clinical concern.^4,5

The 7-character code structure of H35.3212 reflects the ICD-10-CM classification hierarchy for wet AMD, which was designed to align with the clinical management paradigm where treatment decisions — frequency of anti-VEGF injections, escalation to combination therapy, or surgical planning — are driven by laterality and CNV activity status. The 6th character “1” denotes the right eye, while the 7th character “2” specifically indicates inactive CNV with involuted or regressed (not scarred) neovascularization, distinguishing this from H35.3213 (inactive scar) where end-stage fibrovascular scarring has occurred and the prognosis for visual recovery is significantly worse. Coders working in ophthalmology settings — particularly retina subspecialty practices — must be fluent in mapping the clinician’s stage language (e.g., “quiescent CNV,” “regressed membrane,” “dry on OCT”) to the correct 7th character to avoid under-coding or claim denials for anti-VEGF injections requiring stage-specific diagnosis support.^3,4

---

🌳 Code Tree / Hierarchy

H35 — Other retinal disorders ❌ Non-billable
│
├── H35.30 — Unspecified macular degeneration ✅ Billable
├── H35.31 — Nonexudative age-related macular degeneration ❌ Non-billable
│   │
│   ├── H35.3110 — Nonexudative AMD, right eye, stage unspecified ✅ Billable
│   ├── H35.3111 — Nonexudative AMD, right eye, early dry stage ✅ Billable
│   ├── H35.3112 — Nonexudative AMD, right eye, intermediate dry stage ✅ Billable
│   └── H35.3113 — Nonexudative AMD, right eye, advanced atrophic without subfoveal involvement ✅ Billable
│   └── H35.3114 — Nonexudative AMD, right eye, advanced atrophic with subfoveal involvement ✅ Billable
│
├── H35.32 — Exudative age-related macular degeneration ❌ Non-billable
│   │
│   ├── H35.321 — Exudative AMD, right eye ❌ Non-billable (needs 7th character)
│   │   ├── H35.3210 — Exudative AMD, right eye, stage unspecified ✅ Billable
│   │   ├── H35.3211 — Exudative AMD, right eye, with active CNV ✅ Billable
│   │   ├── H35.3212 — Exudative AMD, right eye, with inactive CNV ◀ THIS CODE ✅ Billable
│   │   └── H35.3213 — Exudative AMD, right eye, with inactive scar ✅ Billable
│   │
│   ├── H35.322 — Exudative AMD, left eye ❌ Non-billable (needs 7th character)
│   │   ├── H35.3220 — Exudative AMD, left eye, stage unspecified ✅ Billable
│   │   ├── H35.3221 — Exudative AMD, left eye, with active CNV ✅ Billable
│   │   ├── H35.3222 — Exudative AMD, left eye, with inactive CNV ✅ Billable
│   │   └── H35.3223 — Exudative AMD, left eye, with inactive scar ✅ Billable
│   │
│   ├── H35.323 — Exudative AMD, bilateral ❌ Non-billable (needs 7th character)
│   │   ├── H35.3230 — Exudative AMD, bilateral, stage unspecified ✅ Billable
│   │   ├── H35.3231 — Exudative AMD, bilateral, with active CNV ✅ Billable
│   │   ├── H35.3232 — Exudative AMD, bilateral, with inactive CNV ✅ Billable
│   │   └── H35.3233 — Exudative AMD, bilateral, with inactive scar ✅ Billable
│   │
│   └── H35.329 — Exudative AMD, unspecified eye ❌ Non-billable (needs 7th character)
│
└── H35.33 — Angioid streaks of macula ✅ Billable

When Both Eyes Have Wet AMD But Different Stages — Code Each Separately

If the patient has exudative AMD in both eyes but at different stages — for example, active CNV in the left eye and inactive CNV in the right eye — you must code each eye separately with its own laterality and stage code. Use H35.3212 (right, inactive CNV) + H35.3221 (left, active CNV) rather than the bilateral code H35.323x. The bilateral code is only appropriate when both eyes are at the same stage. Per Retinal Physician coding guidance, this is one of the most common AMD coding errors seen in retina practices.⁴

"Inactive CNV" vs. "Inactive Scar" — Clinical and Coding Distinction

ICD-10-CM H35.3212 (inactive CNV with involuted/regressed neovascularization) and H35.3213 (inactive scar) are not interchangeable. Inactive CNV (H35.3212) means the membrane has regressed but no fibrovascular scar has formed — the patient retains potential for visual stabilization or improvement with continued therapy and remains at risk for reactivation. Inactive scar (H35.3213) indicates end-stage fibrosis, typically associated with permanent central vision loss. The distinction must come from the retinal specialist’s documentation and supported by OCT findings; coders should not infer the stage from visual acuity alone.^4,5

---

✅ Includes

• Wet AMD right eye with involuted choroidal neovascularization — A neovascular membrane that has involuted (folded inward and regressed) following anti-VEGF treatment; this is the primary clinical scenario for H35.3212.
• Wet AMD right eye with regressed choroidal neovascularization — Synonymous with involuted CNV; regression may be documented on OCT-A as decreased flow signal in the previously active CNV complex.
• Exudative AMD right eye post-treatment with CNV regression — Patients who have completed a loading phase of anti-VEGF injections and achieved dryness on OCT fall into this category when the physician documents CNV regression.
• Quiescent neovascular AMD, right eye — Some retinal specialists use the term “quiescent CNV” to describe the inactive phase; this clinical language maps to the 7th character “2” (inactive with involuted/regressed neovascularization).
• Neovascular AMD right eye, inactive phase — The general clinical descriptor “inactive neovascular AMD” aligns with H35.3212 when no scar is documented.

---

❌ Excludes

Excludes 1

There are no Excludes1 notes specific to H35.3212 in the FY2026 ICD-10-CM Tabular List. H35.3212 does not have any condition that is mutually exclusive at the code level; however, coders must apply common-sense mutual exclusivity — a patient cannot have both active CNV (H35.3211) and inactive CNV (H35.3212) in the same right eye simultaneously; only one stage code applies per eye per encounter.

Most Common Stage Coding Error — Active vs. Inactive CNV

The most frequent error in wet AMD coding is assigning the wrong stage — specifically, defaulting to H35.3211 (active CNV) when the patient has achieved treatment response and the physician documents CNV regression or a dry macula on OCT. Conversely, coders sometimes assign H35.3212 (inactive CNV) when the chart actually documents new subretinal fluid or active leakage on the current encounter. The stage must reflect the current visit documentation, not the patient’s historical diagnosis. Review the encounter note, OCT interpretation, and the clinician’s assessment section carefully before assigning the 7th character.^3,4

Excludes 2

• E08.311-E08.359 / E09.311-E09.359 / E10.311-E10.359 / E11.311-E11.359 / E13.311-E13.359 — Diabetic retinal disorders: These codes cover diabeticmacular edema and diabetic retinopathy, which are distinct pathological processes from AMD-related CNV. When a patient has both type 2 diabetes with diabetic retinopathy (e.g., E11.311) AND exudative AMD (H35.3212), both codes must be reported — the AMD code does not replace the diabetic retinal code. This is a clinically important distinction because diabetic macular edema and wet AMD can coexist and both may require treatment (e.g., anti-VEGF for both conditions), but they have separate ICD-10-CM classifications, separate HCC mappings, and potentially separate prior authorization requirements.³

---

📋 Clinical Overview

Wet AMD CNV Activity Stage — Code Selection Guide

Accurate 7th character assignment for H35.32x codes hinges entirely on the clinician’s documentation of CNV activity status, which is determined by retinal imaging and clinical examination at each encounter. This table summarizes the three billable stage options for the right eye (H35.321x) and their distinguishing features.

Feature	H35.3211	H35.3212	H35.3213
7th Character	1 — Active CNV	2 — Inactive CNV (involuted/regressed)	3 — Inactive scar
OCT Finding	Subretinal or intraretinal fluid present; active leakage	Dry macula; no active fluid; CNV membrane visible but not leaking	Fibrovascular scar; disrupted outer retinal layers
Clinical Status	Active disease; typically initiating or continuing anti-VEGF loading	Treatment response; managed on PRN, treat-and-extend, or maintenance schedule	End-stage; limited potential for visual recovery
Anti-VEGF Necessity	Strongly supported; prior auth typically approved	Supportable when monitoring for reactivation; some payers require documentation of CNV presence	Generally not supported for active treatment; monitoring only
Risk of Progression	High; active leakage damages RPE and photoreceptors	Moderate; reactivation risk persists; requires ongoing OCT surveillance	Low; irreversible scarring limits further active disease
CDI Trigger	”Active CNV,” “new SRF,” “fluid on OCT,” “leakage on FA"	"Regressed CNV,” “dry OCT,” “quiescent,” “involuted membrane"	"Scar,” “fibrosis,” “disciform scar,” “fibrovascular scar”

CDI Trigger — Query When Stage Language Is Absent

When the retinal specialist’s note documents wet AMD without explicitly stating the CNV activity stage, this is a CDI and coding query opportunity. A note that reads only “wet AMD, right eye — intravitreal injection performed” is insufficient for 7th character assignment. The clinician must document active, inactive (involuted/regressed), or inactive scar to support the specific code. For risk adjustment purposes, any code billed without this specificity may result in an HCC audit finding or claim edit.^2,5

Manifestations & Symptom Burden

• Metamorphopsia (distorted vision) — Central visual distortion caused by RPE elevation or subretinal fluid displacement; documented by Amsler grid testing; code separately with H53.15 (Visual distortions of shape and size) only when separately evaluated and treated.
• Decreased visual acuity — Central vision loss from macular involvement; document and code with H54.x (Visual impairment) codes only when the clinician explicitly documents visual impairment or legal blindness as a separate condition.
• Scotoma (central) — Central blind spot from RPE and photoreceptor damage in the foveal zone; integral to AMD and generally not coded separately.
• Contrast sensitivity loss — Functional vision loss affecting daily activities; relevant for disability documentation and low vision referral but generally not separately coded.
• Risk of fellow eye involvement — Patients with unilateral wet AMD have a high lifetime risk of developing wet AMD in the contralateral eye; if the left eye has dry AMD, code the left eye status separately (H35.31xx) in addition to H35.3212.

Manifestation Coding for AMD

Symptoms integral to the AMD disease process — such as central visual distortion and macular scotoma — are generally not coded separately per ICD-10-CM Official Guidelines Section I.C.7. However, if the patient has separately documented and managed legal blindness or profound visual impairment caused by the AMD, codes from category H54 (Blindness and low vision) should be added to reflect the full functional impact, which can support medical necessity for low vision services and rehabilitation referrals.³

---

💰 HCC Risk Adjustment

Model	HCC Category	HCC Label	RAF Weight (Approx.)
CMS-HCC V28	HCC 300	Exudative Macular Degeneration	~0.596 (Community, NonDual, Aged)
CMS-HCC V24 (legacy)	HCC 124	Exudative Macular Degeneration	Model-dependent
RAPS (MA)	Maps to HCC 300	Exudative Macular Degeneration	Varies by plan year

ICD-10-CM H35.3212 maps directly to CMS-HCC Category 300 (Exudative Macular Degeneration) under the V28 model, carrying an approximate RAF weight of 0.596 for community-dwelling, non-dual eligible, aged Medicare Advantage enrollees — a significant score reflecting the high cost burden of ongoing anti-VEGF therapy, diagnostic imaging, and specialist management.^1,2 All exudative AMD codes (H35.321x through H35.329x) with any stage designator map to HCC 300, meaning the specific 7th character stage does not alter the HCC mapping, but it absolutely must be present for the code to be billable and for the claim to pass coding edits. Annual recapture is mandatory — the diagnosis must be documented and coded at least once per plan year with MEAT criteria support (Monitor, Evaluate, Assess, Treat) in the clinical record. Payer risk adjustment audits for HCC 300 are common given the high RAF value; documentation must include the retinal specialist’s explicit diagnosis of exudative (wet) AMD with supporting OCT or angiography findings. Missing this HCC in a Medicare Advantage population represents a direct financial impact to the health plan’s risk score and to accurate reflection of the patient’s disease burden.

---

🏥 MS-DRG Assignment

Scenario	MS-DRG	Title	Est. Relative Weight
H35.3212 as PDX, medical management, with MCC	124	Other Disorders of the Eye with MCC	~1.4-1.8
H35.3212 as PDX, medical management, with CC	125	Other Disorders of the Eye with CC	~0.9-1.2
H35.3212 as PDX, medical management, w/o CC/MCC	126	Other Disorders of the Eye without CC/MCC	~0.6-0.8
H35.3212 with vitrectomy procedure	113-117	Orbital / Ocular Procedures	~1.8-3.5
H35.3212 as secondary dx	Varies by PDX	—	Varies

Wet AMD is overwhelmingly managed in the outpatient and ASC settings — inpatient admissions for H35.3212 as PDX are uncommon and typically occur only when surgical intervention (e.g., pars plana vitrectomy for submacular hemorrhage) is required or when a significant complication demands inpatient-level monitoring.⁶ In the rare inpatient scenario with medical management only, the case groups to DRGs 124-126 based on the presence of MCC/CC secondary diagnoses. When vitrectomy or other ocular OR procedures are performed, the DRG shifts to the surgical tier (DRGs 113-117 or related). Coders should always verify the exact DRG through a certified IPPS grouper, as relative weight values fluctuate with each fiscal year update. As a secondary diagnosis on an inpatient stay for a different PDX, H35.3212 may contribute as a CC depending on the PDX — capture it to fully represent the patient’s comorbidity burden. Profee coders in ophthalmology practices should note that the far more relevant payment mechanism for this code is the outpatient/ASC setting, where CPT 67028 (intravitreal injection) and diagnostic imaging CPTs drive reimbursement.

---

🔗 Related ICD-10-CM Codes

Exudative AMD Staging Siblings (Right Eye):

• H35.3210 — Exudative AMD, right eye, stage unspecified — use only when staging cannot be determined; audit risk for risk adjustment
• H35.3211 — Exudative AMD, right eye, with active CNV — active leakage present; typically requires more frequent anti-VEGF
• H35.3213 — Exudative AMD, right eye, with inactive scar — end-stage; fibrovascular scar; permanent central vision loss
• H35.3222 — Exudative AMD, left eye, with inactive CNV — bilateral disease, different stage; code separately from H35.3212

Related Retinal and Comorbid Codes:

• H35.3112 — Nonexudative AMD, right eye, intermediate dry stage — contralateral or same-eye dry AMD component; dry and wet AMD can coexist
• H35.81 — Retinal edema — may coexist with AMD; code only when separately documented
• H44.2C1 — Degenerative myopia with choroidal neovascularization, right eye — a competing CNV etiology; AMD CNV and myopic CNV are distinct; verify etiology before coding
• Z79.899 — Other long-term (current) drug therapy — may be used to document ongoing anti-VEGF therapy when clinically relevant for medication reconciliation purposes

---

🛠️ Commonly Associated CPT Codes

• 67028 — Intravitreal injection of a pharmacologic agent (separate procedure): This is the primary procedure code for anti-VEGF injections (ranibizumab/Lucentis, aflibercept/Eylea, bevacizumab/Avastin, faricimab/Vabysmo) administered to treat wet AMD; H35.3212 directly supports medical necessity. Append modifier -RT for right eye. Payers may require prior authorization tied to the specific ICD-10-CM code and agent’s HCPCS code (e.g., J0178 for aflibercept, J2778 for ranibizumab).^4,6
• 92134 — Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral (OCT): OCT is the gold standard for monitoring CNV activity status and determining 7th character specificity in H35.3212 — the “inactive” designation is supported by OCT showing a dry macula. Append -RT for right eye only. CMS LCD policy (A57561) specifies covered diagnoses for OCT; H35.3212 is a covered indication. Do not bundle with 67028 on the same date unless payer policy permits separate billing.⁵
• 92235 — Fluorescein angiography (FA) with interpretation and report, unilateral or bilateral: FA is used to evaluate CNV activity, leakage pattern, and treatment response; particularly useful when OCT findings are inconclusive about active vs. inactive CNV. H35.3212 supports medical necessity. Note NCCI bundling considerations when performed same-day as other ocular imaging.
• 92240 — Indocyanine green angiography (ICGA) with interpretation and report: ICGA evaluates choroidal circulation and can detect occult CNV not visible on FA; used in complex wet AMD cases or when polypoidal choroidal vasculopathy (PCV) is suspected as an AMD variant. H35.3212 may support this study when monitoring for reactivation.
• 92002 / 92004 / 92012 / 92014 — Ophthalmological services, E/M (established/new, intermediate/comprehensive): Office visit E/M codes for the retinal specialist’s examination and medical decision-making at each AMD encounter; H35.3212 is the primary diagnosis supporting the visit. Use 92014 (comprehensive, established patient) for most wet AMD monitoring visits given the complexity of the ocular examination and medical decision-making involved.
• 67210 — Destruction of localized lesion of retina (e.g., macular photocoagulation), 1 or more sessions; laser surgery: Laser photocoagulation is now rarely used for wet AMD since anti-VEGF became standard of care, but may be applicable in select cases of extrafoveal CNV; H35.3212 supports this procedure when the clinical scenario is documented. Verify that laser coagulation is the documented treatment modality.

NCCI Bundling Considerations

When CPT 92134 (OCT) and CPT 67028 (intravitreal injection) are performed on the same date of service, NCCI Procedure-to-Procedure (PTP) edits may apply depending on the payer — some commercial payers bundle diagnostic imaging performed on the same day as the injection procedure, while Medicare Part B generally allows separate billing with appropriate documentation supporting the medical necessity of the imaging at that visit.⁴ Modifier -59 (Distinct Procedural Service) or -XS (Separate Structure, for facility claims) may be required to bypass the bundle when the OCT is performed at a separate time or for a distinct clinical reason from the injection. FA (92235) and ICGA (92240) also carry potential NCCI edits when billed together on the same date; review the current CMS NCCI PTP edit table quarterly for updates, as ophthalmology imaging edits are frequently revised. Always verify individual payer LCD/NCD policies in addition to NCCI edits, as Medicare Advantage and commercial plans may impose additional restrictions beyond federal NCCI guidelines.

---

🔬 ICD-10-PCS Crosswalk

• 3E0C3GC — Introduction of Other Therapeutic Substance into Eye, Percutaneous Approach: This ICD-10-PCS code is used when an intravitreal pharmacologic injection (anti-VEGF agent) is documented for inpatient encounters; for outpatient/ASC encounters, CPT 67028 applies instead. Facility coders should confirm the correct body part character and approach character with the operative note.
• B307ZZZ — Plain Radiography of Right Eye: Not commonly used for AMD, but included for reference; OCT and fluorescein angiography are performed under ophthalmologic imaging PCS codes when documented in the inpatient record.
• 08JX0ZZ — Inspection of Right Eye, Open Approach / 08JX3ZZ — Inspection of Right Eye, Percutaneous Approach: Used when a formal ocular examination is documented as a separately reportable procedure in the inpatient record; most routine ophthalmology consultations are reported under E/M rather than PCS procedure codes.
• 08B63ZZ — Excision of Retina, Right Eye, Percutaneous Approach: Applicable in rare inpatient scenarios where vitreoretinal surgery (e.g., excision of submacular fibrovascular membrane) is performed for end-stage wet AMD complications; verify with the operative note that excision, not simply drainage or inspection, is the documented root operation.

---

💊 Coding Scenarios and Examples

Scenario 1 — Routine Anti-VEGF Injection Visit, Inactive CNV A 74-year-old female Medicare Advantage patient presents to a retina specialist for a scheduled intravitreal injection visit. She has a documented history of wet AMD in the right eye, currently on a treat-and-extend aflibercept (Eylea) protocol. OCT today shows a dry macula with no subretinal fluid; the clinician documents “exudative AMD, right eye, with inactive choroidal neovascularization — extending interval to 10 weeks.” Intravitreal aflibercept 2mg is injected into the right eye.

• Diagnosis: H35.3212 — Exudative AMD, right eye, with inactive CNV
• CPT: 67028-RT — Intravitreal injection, right eye
• HCPCS: J0178 — Injection, aflibercept (Eylea), 1mg (bill in units based on dose administered)
• Sequencing: H35.3212 is the PDX supporting both the E/M and the injection procedure. HCC 300 is captured for risk adjustment purposes. CDI note: The 7th character “2” is supported by the OCT finding of “dry macula” and the clinician’s specific stage documentation — this is exactly the level of specificity needed to withstand a risk adjustment audit.

Scenario 2 — Bilateral Wet AMD, Different Stages Each Eye A 79-year-old male presents for bilateral intravitreal injections. OCT right eye shows a dry macula with regressed CNV membrane; OCT left eye shows new subretinal fluid with active leakage. Clinician documents: “wet AMD, right eye, inactive CNV with regressed membrane; wet AMD, left eye, with active choroidal neovascularization.” Bilateral injections are performed.

• Diagnosis 1: H35.3212 — Exudative AMD, right eye, with inactive CNV
• Diagnosis 2: H35.3221 — Exudative AMD, left eye, with active CNV
• CPT: 67028-RT — Intravitreal injection, right eye
• CPT: 67028-LT — Intravitreal injection, left eye
• Sequencing: Both codes are required because bilateral AMD is at different stages — the bilateral code H35.3232 is not appropriate here. Each eye’s code independently supports medical necessity for its respective injection. CDI note: This scenario is precisely why the bilateral code is insufficient when stages differ across eyes — submitting H35.323x without stage specificity would be a coding error and risk adjustment inaccuracy.

Scenario 3 — Inpatient Admission for Submacular Hemorrhage Complicating Wet AMD An 81-year-old male is admitted inpatient after acute vision loss in the right eye. Fundus examination and OCT reveal a large submacular hemorrhage complicating known wet AMD, right eye. The attending documents “submacular hemorrhage with compression of foveal photoreceptors, right eye, complicating exudative AMD with previously inactive CNV — now with evidence of reactivation.” Pars plana vitrectomy with pneumatic displacement of hemorrhage is performed.

• PDX: H35.6110 — Subretinal hemorrhage, right eye (principal diagnosis driving admission/surgery) — verify exact code with operative note
• Secondary: H35.3211 — Exudative AMD, right eye, with active CNV (updated to active given documented reactivation)
• ICD-10-PCS: 08B63ZZ — Surgery procedure code per operative note (verify root operation)
• Sequencing: The hemorrhage drives the admission and surgical intervention; AMD is secondary. Note the stage has shifted from H35.3212 to H35.3211 based on the current encounter documentation of CNV reactivation — coders must code the current encounter status, not the historical inactive stage. CDI note: This scenario illustrates how a patient’s AMD stage code can change encounter-to-encounter; always code to the stage documented at the current visit.

---

⚠️ Coding Pitfalls and Tips

• Pitfall 1 — Submitting H35.321 without the 7th character. The 6-character code H35.321 (Exudative AMD, right eye) is non-billable and will be rejected on a claim. This is the most common wet AMD billing error seen in retina practices. Every claim must include the full 7-character code — H35.3210 through H35.3213 — and the stage must be supported by the encounter documentation. Automated claim scrubbers in most practice management systems should catch this, but manual review during coding is still essential.^3,4
• Pitfall 2 — Using H35.3210 (stage unspecified) as a default. When the clinician’s note does not explicitly document the CNV stage, coders sometimes default to H35.3210 (stage unspecified) for ease. While this is technically billable, it is a risk adjustment miss for HCC 300 — all stage-specific codes (H35.3211-H35.3213) map to HCC 300 identically, but the unspecified code may trigger queries during payer audits and reflects incomplete documentation. Instead of defaulting to unspecified, generate a CDI query asking the provider to document the CNV activity status — it takes seconds and protects both the coding accuracy and the HCC capture.^2,4
• Pitfall 3 — Failing to update the stage code when CNV activity changes. Wet AMD is a dynamic disease; a patient who was coded as H35.3212 (inactive CNV) at the last visit may have H35.3211 (active CNV) documented at the current visit due to CNV reactivation. Always code to the current encounter’s documented stage, not the historical or carry-forward diagnosis. Copying forward a prior visit’s ICD-10-CM code without confirming the current CNV status is a compliance risk and a clinical documentation accuracy failure.³
• Pitfall 4 — Assigning the bilateral code when stages differ. When a patient has wet AMD in both eyes but at different stages, coders must use separate laterality-specific codes for each eye rather than the bilateral H35.323x code. The bilateral code is appropriate only when both eyes are at the same stage. Assigning H35.3232 (bilateral inactive CNV) when the right eye is inactive and the left eye is active is a coding inaccuracy that misrepresents the clinical picture, may cause prior authorization denials, and introduces risk adjustment inaccuracies.⁴
• Pitfall 5 — Missing HCC 300 in Medicare Advantage populations. In the outpatient setting, H35.3212 must be documented and coded at least once per plan year for Medicare Advantage risk adjustment purposes. Some ophthalmology practices code only the injection CPT and HCPCS codes without ensuring the ICD-10-CM diagnosis is submitted on a claim that crosses to the MA plan’s risk adjustment data system. Ensure that the diagnosis code is present on every claim, not just injection claims — the E/M visit claim is equally valid for HCC capture, provided MEAT criteria are met in the documentation.^1,2
• Pitfall 6 — Ignoring the Excludes2 note for concurrent diabetic retinopathy. When a patient has both wet AMD (H35.3212) and diabetic retinopathy (e.g., E11.311 — Type 2 DM with mild nonproliferative retinopathy, right eye), both codes must be submitted. The Excludes2 note confirms these can coexist and be coded together. Omitting the diabetic retinopathy codes in a diabetic AMD patient is both a coding inaccuracy and a missed opportunity to capture additional HCC-mapped diagnoses (diabetes with complications maps to HCC 37/38 in V28), directly impacting risk adjustment completeness.³

---

📚 Sources

1. BDA Demos / CMS. Exudative Macular Degeneration CMS-HCC Category 300, V28 Model. BDADemos.com. April 2023. https://bdademos.com/wp-content/uploads/2023/04/HCC-300-Exudative-Macular-Degeneration-V28.pdf
2. Highmark / Providers. Exudative Macular Degeneration Coding and Documentation Tips — HCC 300. Highmark Provider Resource Center. https://providers.highmark.com
3. Centers for Medicare & Medicaid Services (CMS). ICD-10-CM Official Guidelines for Coding and Reporting, FY2026. CMS.gov. 2025. https://www.cms.gov/files/document/fy-2026-icd-10-cm-coding-guidelines.pdf
4. Retinal Physician. Coding Q&A: Coding Guidelines for Wet AMD. RetinalPhysician.com. February 2026. https://www.retinalphysician.com/issues/2025/april/coding/
5. CMS Medicare Coverage Database. Billing and Coding: Scanning Computerized Ophthalmic Diagnostic Imaging (OCT) — Article ID 56916. CMS.gov. 2024. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56916&ver=25
6. Genentech / Lucentis. Billing and Coding for Wet AMD — Lucentis Reference Guide. Lucentis.com. https://www.lucentis.com/content/dam/gene/accesssolutions/pdfs/coding/LUCENTIS-Billing-Coding-for-wet-AMD.pdf
7. Outsource Strategies International. Coding Macular Degeneration — A Common Age-Related Eye Condition. OutsourceStrategies.com. 2025. https://www.outsourcestrategies.com/blog/coding-macular-degeneration-common-age-related-eye-condition/
8. AAPC Codify. ICD-10 Code H35.3212 — Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization. AAPC.com. https://www.aapc.com/codes/icd-10-codes/H35.3212